In their third discussion of the topic in two months, US FDA advisory committee members offered the agency their clearest direction on how coronavirus vaccine sponsors should handle placebo controls in clinical trials, although even supporters of the consensus choice acknowledged it was not ideal.
The Vaccines and Related Biological Products Advisory Committee members indicated on 17 December that Moderna, Inc. should follow the...







